StockNews.AI

Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results

StockNews.AI • 1 minute

BIOAMNDXCM
High Materiality8/10

Information

Company to present at the 44th Annual JP Morgan Healthcare Conference Company to present at the 44th...

Original source

AI Summary

Cytek Biosciences projects approximately $201 million in total revenue for 2025, indicating solid growth with significant increases in the fourth quarter. Their upcoming presentation at the JP Morgan Healthcare Conference may energize investor sentiment, especially as they prepare to provide 2026 financial guidance in February.

Sentiment Rationale

The strong revenue growth trajectory during Q4 coupled with positive management commentary enhances investor confidence. Past instances of earnings announcement-driven stock movements illustrate potential for price appreciation dependent on disclosed revenue and guidance.

Trading Thesis

Invest in CTKB for potential bullish movement ahead of the earnings call and conference.

Market-Moving

  • Strong Q4 revenue suggests upward momentum, potentially increasing investor confidence.
  • Presentation at JP Morgan Conference may attract institutional interest.
  • Future guidance could drive stock price volatility depending on forecasts.
  • Positive sales trends in key markets indicates robust competitive positioning.

Key Facts

  • Cytek Biosciences expects $201 million in total revenue for 2025.
  • Fourth quarter revenue projected at $62 million, up 19% sequentially.
  • CEO cites strong growth in Services, Reagents, and Asia Pacific market.
  • Cytek will present at the JP Morgan Healthcare Conference on January 14, 2026.
  • 2026 guidance will be provided during the earnings call in late February.

Companies Mentioned

  • Cytek Biosciences, Inc. (CTKB): Leading cell analysis solutions company with growing revenue profile.

Corporate Developments

This news falls under 'Corporate Developments' as it highlights Cytek's revenue growth and future plans, influencing investor sentiment and expectations. The upcoming conference could serve as a catalyst for share price movements in the short term.

Cytek Biosciences Reports Preliminary Revenue Results for Q4 and Full Year 2025

FREMONT, Calif., Jan. 12, 2026 – Cytek Biosciences, Inc. (Nasdaq: CTKB), a leader in cell analysis solutions, has announced its preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2025, showcasing significant growth in its revenue streams.

Impressive Revenue Growth in 2025

For the full year 2025, Cytek anticipates total revenue of approximately $201 million. This demonstrates a year-over-year increase, reflecting the company's robust performance across diverse markets.

The preliminary results indicate expected revenue of around $62 million for the fourth quarter of 2025. This figure marks an 8% increase compared to the same quarter in 2024 and a remarkable 19% rise compared to the third quarter of 2025.

CEO Insights on Growth Trends

Dr. Wenbin Jiang, CEO of Cytek Biosciences, noted the significance of these results, stating, “Our fourth quarter revenue growth over the prior year represents a meaningful acceleration of growth compared to the prior quarters in 2025...”

  • Continued strong growth in Services and Reagents
  • Significant revenue increase in the Asia Pacific region
  • Positive growth return in instrument sales in EMEA

Dr. Jiang emphasized the company's positioning in the flow cytometry market, highlighting Cytek's commitment to achieving sustainable growth and profitability through effective execution across its product portfolio.

Upcoming Financial Reporting and Events

Please note that the preliminary financial results provided are not exhaustive and have not been audited by an independent accounting firm. The actual revenue figures may differ due to the completion of the company's year-end closing and auditing procedures.

Cytek plans to report its complete financial results for the fourth quarter and full year ended December 31, 2025, along with its 2026 financial guidance during an earnings call scheduled for late February 2026.

In addition, Cytek will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 14, 2026. The presentation will commence at 5:15 PM Pacific Time / 8:15 PM Eastern Time, with live and archived webcasts available on the Investors section of the company website.

About Cytek Biosciences

Cytek Biosciences, Inc. (Nasdaq: CTKB) is pioneering next-generation cell analysis solutions with its patented Full Spectrum Profiling™ (FSP®) technology. The company is dedicated to delivering high-resolution and high-sensitivity cell analysis tools, including:

  • Cytek Aurora™
  • Northern Lights™
  • Cytek Orion™ reagent systems
  • Enhanced Small Particle™ (ESP™) detection
  • Amnis® and Guava® flow cytometers and imaging products

With its headquarters in Fremont, California, and global distribution channels, Cytek is positioned to enhance research capabilities across various scientific fields.

For more information about Cytek Biosciences and its innovative products, visit www.cytekbio.com.

Disclaimer: Cytek’s products are for research use only and not for diagnostic procedures, except for specific products available under certain conditions in designated regions.

Related News